Opinion
Hosted on MSN5hOpinion
A New Fad: Microdosing Ozempic
A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). I was asked to discuss the topic on ...
Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...
Eli Lilly ( LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound.
Eli Lily continues to dominate the weight loss market, willing to crush any competitor that threatens its dominance. One such ...
Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the branded drugs, Lilly on Wednesday said it would sell a version of Zepbound ...
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...